Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axis-Shield to develop HBP test after Hansa deal

This article was originally published in Clinica

Executive Summary

Axis-Shield is to develop a new test for severe sepsis and septicaemia after gaining exclusive, worldwide access to Hansa Medical’s heparin-binding protein (HBP) diagnostic assay. Axis-Shield will develop the assay and seek commercial partners to incorporate the new technology into high-throughput systems. Lund, Sweden-based Hansa said that it has carried out initial studies that suggest serum levels of HBP are a “promising predictor for severe sepsis compared to inflammation markers [used in tests] presently on the market”. Financial terms of the deal were not disclosed. According to Axis-Shield, more than 200,000 people die from sepsis or septicaemia each year. The firm claims that “for every hour that severe sepsis onset is identified and properly treated, survival rates increase by 7.5%”.

You may also be interested in...



Hansa Medical Nears Market With IdeS For Sensitized Transplant Patients

A product derived from a bacterial protein, IdeS, could be the first medicine from Sweden's Hansa Medical to tackle a serious unmet need, transplant patients unable to find a donor match because of HLA sensitization.

Alere aided by professional diagnostics sales in fourth quarter

Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.

Integra and Stout to work on expandable interbody device

Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.

Topics

UsernamePublicRestriction

Register

MT042923

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel